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In This IssueTargeting Purine Metabolism in Neurodegeneration
PAGE 505
Akizu et al. identify a purine metabolism disorder, manifested in the form of early-onset pontocerebellar
hypoplasia—due to loss of brainstem and cerebellar parenchyma—caused by mutations in the gene
AMPD2. Loss of AMPD2 causes guanine nucleotide depletion and protein synthesis inhibition, ultimately
leading to neural toxicity. Bypassing this block in de novo purine synthesis prevents neurodegeneration,
suggesting that AMPD2 deficiency is a potentially treatable neurodegenerative disorder.Schizophrenia Genes in Time and Space
PAGE 518
With the identification of mutations associated with complex psychiatric diseases comes the challenge of
placing them in a biological context to inform disease etiology and treatment. Gulsuner et al. integrate identification of damaging de novo
mutations in persons with schizophrenia, but not their healthy siblings, with transcript data from human brain samples at different points in
development. They reveal a network defined by coexpression specifically in the prefrontal cortex during fetal development, implicating an
important role for cortical neurogenesis in schizophrenia.Cooperating with Relatives Key to Success in Speciation
PAGE 530
Stefflova et al. examine themicroevolutionary processes that create different transcription factor binding patterns betweenmammals to shed
light on the regulatory mechanisms partially underlying speciation. The authors use the high-quality genomes of multiple mouse species to
analyze what mechanisms drive interspecies differences in transcriptional regulation. Maintaining cooperativity of binding, not direct genetic
variation at individual TF binding sites, appears to be the dominant driver of TF binding divergence in closely related and recently speciated
mammals.Demethylase Drives Site-Specific CNV
PAGE 541
Copy number variation (CNV) is common in cancer and contributes to genomic instability. Black et al. now demonstrate that overexpression of
the lysine demethylase KDM4A/JMJD2A promotes copy gain at specific sites in the genome in both cell lines and tumors. KDM4A associates
with the replication machinery and induces transient copy gain via rereplication, suggesting a model for how site-specific CNVs could
originate during tumorigenesis and demonstrating that overexpression of specific chromatin modulators can produce CNVs.Skp2 the Next Phase in Cancer Treatment
PAGE 556
The Skp2 subunit of the SCF E3 ligase complex is often overexpressed in cancers and is known to promote invasion and metastasis.
Chan et al. carry out a virtual screen for compounds that inhibit Skp2 activity and identify one that blocks the interaction of Skp2 with
Skp1, thereby selectively inhibiting the Skp2 SCF complex. The inhibitor suppresses cancer stem cell renewal and shows antitumorigenic
activity in animal models, identifying kp2 as a promising target for cancer treatment.DUB-ling Up for Specificity
PAGE 609
Membrane protein quality control employs ubiquitin ligase complexes that inspect nascent polypeptides and preferentially polyubiquitinate
those warranting degradation. However, ligase-substrate interactions alone cannot account for substrate selectivity. Using in vitro
reconstitution of a membrane degradation system, Zhang et al. show that optimal substrate discrimination requires deubiquitinases
(DUBs) to counteract the ligases and exaggerate the differential polyubiquitination among potential clients.
DUBs have greater access to well-folded substrates that showweaker interactions with the ligase, protect-
ing them from degradation.Aiding and a-BET-ting Heart Failure
PAGE 569
BET bromodomain proteins, chromatin ‘‘readers’’ that interact with acetylated histones, are shown by
Anand et al. to be critical coactivators of a pathological cardiac gene expression program induced by
stress. The BET bromodomain proteins facilitate release of pausedRNA polymerase II at genes key to heart
failure. Small molecule inhibition of the BET bromodomain blocks pause-release and protects against path-
ological cardiac remodeling and heart failure.Cell 154, August 1, 2013 ª2013 Elsevier Inc. 469
Keeping an Intron Makes the Difference
PAGE 583
Intron retention, leading to nonsense-mediated decay (NMD), has been long considered a consequence of
aberrant splicing. Analyzing global changes in gene expression, Wong et al. show that intron retention
coupled to NMD is a conserved regulatory mechanism that limits the expression of multiple genes during
white blood cell differentiation. Artificially increasing the expression of one of these genes interferes with
granulocyte differentiation, demonstrating that intron retention is a normal physiological process likely to
be found in other tissue types as well.
Trash Talk Calls a Stop to Replication
PAGE 623Cells can inhibit DNA replication in response to cellular stress to limit the risk of genomic instability. Jonas et al. show thatmisfolded proteins in
bacteria can allosterically stimulate the protease Lon to recognize and degrade the replication initiator DnaA, causing a G1 arrest during times
of proteotoxic stress. Misfolded proteins thus directly influence the activity of proteases and are not simply passive substrates. The results
delineate a pathway that links cellular stress to the initiation of DNA replication.
Synaptic Switches in Addiction
PAGE 637
Addiction is dependent on dopamine receptor signaling, and Park et al. now uncover a D1 dopamine receptor signaling pathway that
establishes a state of synaptic plasticity required for cocaine-dependent behavioral changes. Signaling is coordinately dependent on
phosphorylation of the glutamate receptor protein mGluR5, induction of activity-dependent gene Homer1a, and the prolyl isomerase activity
of Pin1, which together potentiate NMDAR-mediated currents. The results suggest that targeting this pathway in corticostriatal synapsesmay
be a strategy for treating addiction.
Portable Energy Generator for Angiogenesis
PAGE 651
Vessel sprouting during angiogenesis requires the induction of migrating tip cells and proliferating stalk cells. De Bock et al. report that
glycolysis, driven by the glycolytic activator PFKFB3, fosters these processes. Mitochondria are excluded from lamellipodia in tip cells,
whereas PFKFB3 and other glycolytic enzymes are compartmentalized there with F-actin, suggesting a mechanism for how glycolysis can
be harnessed to generate energy for motile structures.
Tumors Gain Monopoly over Insulin
PAGE 664
Using Drosophila as a model system, Hirabayashi et al. provide an explanation for the paradox of how cancer cells retain insulin sensitivity
under conditions in which the organism is insulin resistant. Ras/Src-activated cells orchestrate a Wingless-dependent pathway that directs
elevated Insulin receptor expression. As a result, transformed cells monopolize the elevated insulin and glucose available in diabetic
conditions, providing fuel that promotes further transformation.
PQM Extends Lifespan PDQ
PAGE 676
The insulin/IGF-1 signaling pathway modulates stress responses and lifespan through regulation of the DAF-16/FOXO transcription factor.
Combining computational andexperimental approaches, Tepper et al. identify PQM-1 as a newplayer in this pathway and show that it activates
a subsetofDAF-16-responsivegenes inworms.PQM-1andDAF-16usedifferent binding sites andantagonize eachother’s nuclear localization.
The nuclear levels of PQM-1 decrease with age, explaining the age-related decrease in the expression of many developmental genes.
O Rats!
PAGE 691
Atanur et al. present complete sequences and evolutionary analyses of genomes of 27 laboratory rat strains, including ones modeling com-
mon diseases such as hypertension and diabetes. Over 13million variants and genes contributing to disease phenotypes are identified. Many
of the identified rat loci overlap with previouslymapped loci for related traits in humans. These findings pro-
vide a key resource for comparative genomic studies in rat and other mammals and for understanding of
shared and individual mechanisms leading to complex disease phenotypes.
Import-Export Business for b-Barrels
PAGE 596
The biogenesis of mitochondrial b-barrel proteins begins with their import into the mitochondria by TOM
translocases, followed by export into the outer mitochondrial membrane by SAM translocases. Qiu et al.
develop a native assay to monitor b-barrel folding in intact mitochondria and find that the two translocases
form a supercomplex that promotes the channeling of precursor proteins from one translocase to the other
to ensure proper assembly of b-barrel proteins in the mitochondrial membrane.Cell 154, August 1, 2013 ª2013 Elsevier Inc. 471
